meta-analysis | Q815382 |
scholarly article | Q13442814 |
P50 | author | Oliver W Press | Q50211588 |
Muhammad A Mir | Q57616746 | ||
Sergei Syrbu | Q59690735 | ||
Brian K Link | Q61054699 | ||
Matthew J. Maurer | Q74084050 | ||
Susan L Slager | Q92530010 | ||
P2093 | author name string | Stephen M Ansell | |
William R Macon | |||
James R Cerhan | |||
Jonathan W Friedberg | |||
Michael LeBlanc | |||
Thomas Witzig | |||
Steven C Ziesmer | |||
Thomas Habermann | |||
Anne Novak | |||
P2860 | cites work | MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. | Q27851888 |
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
Chemokines, chemokine receptors, and cancer metastasis | Q28297436 | ||
Oncogenically active MYD88 mutations in human lymphoma | Q28301648 | ||
The many roles of chemokines and chemokine receptors in inflammation | Q29618880 | ||
Soluble IL-2 receptor and beta-2 microglobulin as possible serologic markers of neurologic disease in HTLV-1 infection | Q33777159 | ||
IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma | Q34198061 | ||
Chemokines: roles in leukocyte development, trafficking, and effector function | Q34203393 | ||
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. | Q34646321 | ||
Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma | Q35031964 | ||
Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma | Q35212373 | ||
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma | Q35858092 | ||
Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. | Q35866406 | ||
The clinical course of follicular lymphoma | Q36031839 | ||
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. | Q36195016 | ||
Stromal cell contribution to human follicular lymphoma pathogenesis. | Q36208267 | ||
Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study | Q36354265 | ||
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. | Q36628291 | ||
Non-hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort | Q36680965 | ||
Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment | Q37051364 | ||
A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma | Q37083956 | ||
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience | Q37083964 | ||
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource | Q37132380 | ||
A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders | Q37265471 | ||
Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma | Q37402310 | ||
Chemokines in cancer related inflammation | Q37816561 | ||
Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. | Q38112911 | ||
Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype | Q39257959 | ||
Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells | Q39733717 | ||
IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice | Q39788067 | ||
Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition | Q39869706 | ||
IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome | Q40133010 | ||
Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients | Q44460966 | ||
Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease | Q45028553 | ||
Elevated soluble IL-2 receptor levels correlate with tumor bulk of follicular lymphomas with intestinal involvement | Q45258119 | ||
Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival. | Q45937516 | ||
Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. | Q46531281 | ||
Improved survival of follicular lymphoma patients in the United States. | Q50764033 | ||
Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. | Q52574053 | ||
Predictive value of prognostic indices in patients with follicular lymphomas. | Q53241661 | ||
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. | Q53251676 | ||
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. | Q53261993 | ||
Follicular lymphoma international prognostic index. | Q53289840 | ||
Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. | Q53330746 | ||
The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. | Q53342545 | ||
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells | Q57279527 | ||
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells | Q60609607 | ||
Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome | Q60685678 | ||
Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases | Q67992322 | ||
Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure | Q72178748 | ||
Expression of chemokine receptor CXCR3 and its ligand, mig, in gastric and thyroid marginal zone lymphomas. Possible migration and autocrine mechanism | Q73251449 | ||
Serum concentration of the soluble interleukin-2 receptor in vitiligo patients | Q77361391 | ||
Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients | Q79297583 | ||
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma | Q79405030 | ||
Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients? | Q80206065 | ||
Meta-analysis to evaluate the role of interferon in follicular lymphoma | Q81346749 | ||
Prognosis of follicular lymphomas | Q82717691 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | anakinra | Q415411 |
P304 | page(s) | 992-998 | |
P577 | publication date | 2014-11-24 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma | |
P478 | volume | 125 |
Q92429945 | An RNA Aptamer-Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients |
Q42153043 | Application of mid-infrared (MIR) microscopy imaging for discrimination between follicular hyperplasia and follicular lymphoma in transgenic mice |
Q38850729 | Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma |
Q45931583 | CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. |
Q37429985 | CXCL9: evidence and contradictions for its role in tumor progression |
Q50099990 | Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. |
Q26773194 | Diagnosis of follicular lymphoma of the gastrointestinal tract: A better initial diagnostic workup |
Q64244584 | Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial |
Q102071906 | Expression and role of MIG/CXCR3 axis in mantle cell lymphoma |
Q38873898 | Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis |
Q47756618 | Gastrointestinal follicular lymphoma: Current knowledge and future challenges |
Q52562303 | Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. |
Q39901834 | Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma |
Q58793783 | Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies |
Q51055200 | Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. |
Q52865502 | Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. |
Q28073262 | Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How |
Q33722638 | Systemically Infused Mesenchymal Stem Cells Show Different Homing Profiles in Healthy and Tumor Mouse Models |
Q92879880 | The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment |
Q50710717 | Unmet needs in the first-line treatment of follicular lymphoma. |
Search more.